KORU Medical Systems(US:KRMD)2025-08-06 20:08Revenue Growth - Total net revenues increased by $1.8 million, or 20.9%, to $10.2 million for Q2 2025 compared to $8.4 million in Q2 2024[5] - Domestic core revenues were $7.1 million, a 15.3% increase year-over-year, driven by higher consumable volumes and market share gains[6] - International core revenues rose to $2.2 million, a 33.9% increase from the prior year, attributed to higher consumable and pump volumes[7] - Pharma Services and Clinical Trials net revenues reached $0.9 million, a 42.1% increase over the prior year period[6] - Net revenues for the three months ended June 30, 2025, were $10,194,800, representing a 20.9% increase from $8,430,089 in the same period of 2024[25] Profitability - Gross profit increased by $1.0 million, or 18.2%, to $6.5 million, with a gross margin of 63.5%[8] - Gross profit for the six months ended June 30, 2025, was $12,522,104, up from $10,583,048 in 2024, indicating a 18.3% growth[25] - The net loss for the six months ended June 30, 2025, was $1,373,105, a decrease from $2,924,673 in 2024, reflecting a 53% improvement[27] - The company reported a basic and diluted net loss per share of $0.03 for the six months ended June 30, 2025, compared to a loss of $0.06 in 2024, showing a 50% improvement[25] Expenses - Total operating expenses for Q2 2025 were $6.8 million, a slight increase of 1.7% from the prior year[9] - Operating expenses for the three months ended June 30, 2025, totaled $6,788,424, slightly higher than $6,671,784 in 2024, marking a 1.8% increase[25] - Research and development expenses for the six months ended June 30, 2025, were $2,309,398, down from $2,609,907 in 2024, a decrease of 11.5%[25] Cash Position - Ending cash balance was $8.1 million, reflecting a quarterly cash usage of $0.6 million[12] - Cash and cash equivalents at the end of the period were $8,054,716, down from $10,458,001 at the end of June 2024, representing a decrease of 22.9%[27] Guidance and Future Outlook - The company raised its full-year 2025 revenue guidance to $39.5 - $40.5 million, representing growth of 18% - 20%[17] - Adjusted EBITDA for Q2 2025 was $0.3 million, compared to an adjusted EBITDA loss of $0.4 million in Q2 2024[11] - Non-GAAP adjusted EBITDA for the six months ended June 30, 2025, was $14,943, compared to a loss of $1,312,913 in 2024, indicating a significant turnaround[34] Share Information - The weighted average number of common shares outstanding for the three months ended June 30, 2025, was 46,193,709, compared to 45,811,373 in 2024, an increase of 0.8%[34] Product Development - The company submitted a 510(k) filing to add a new drug to the Freedom Infusion System, indicating ongoing product development efforts[4] Other Income - Total other income for the six months ended June 30, 2025, was $201,911, slightly down from $228,727 in 2024, reflecting a decrease of 11.7%[25]